This occurred despite the presence of endogenous CX3CL1 (at low levels due to HFD feeding [20]), suggesting that CX3CL1-s overexpression could have pharmacological benefits for obesity treatment. Here, CX3CL1 is linked to obesity due to melanocortin 4 receptor deficiency.